Sarepta Therapeutics Inc. (S1RP34)

Overview

Sarepta Therapeutics, Inc. is a forefront commercial-stage biopharmaceutical entity devoted to pioneering RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities aimed at the treatment of rare diseases. Since its inception in 1980, the company has established itself as an innovator in the field, located in the renowned biotech hub of Cambridge, Massachusetts. Through strategic collaborations and license agreements with prestigious institutions like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, and universities such as Florida and Duke, as well as with dynamic biotech innovators like Dyno Therapeutics, Hansa Biopharma, Genethon, and StrideBio, Sarepta Therapeutics has pushed the boundaries of genetic medicine, focusing on diseases with significant unmet medical needs.

Products and Services

• EXONDYS 51 Injection

A groundbreaking therapy designed to treat Duchenne muscular dystrophy (Duchenne) in patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. This therapy represents a beacon of hope for those affected by this rare genetic condition, offering a targeted approach to manage its progression.

• VYONDYS 53

Aimed specifically at Duchenne patients with a confirmed mutation of the dystrophin gene that can benefit from exon 53 skipping. VYONDYS 53 exemplifies the company's tailor-made approach to treating genetic disorders, addressing the needs of a specific subset of the Duchenne community.

• AMONDYS 45

This therapeutic solution serves the Duchenne community by targeting patients with specific confirmed mutations of the dystrophin gene. AMONDYS 45 represents Sarepta Therapeutics' commitment to expanding treatment options for those affected by Duchenne muscular dystrophy, emphasizing personalized healthcare solutions.

• ELEVIDYS

As an adeno-associated virus-based gene therapy, ELEVIDYS is focused on treating ambulatory pediatric patients aged 4 through 5 years with Duchenne, who have a confirmed mutation in the Duchenne gene. This gene therapy approach marks a significant advancement in treating genetic disorders, providing hope for younger patients and their families.

• SRP-5051

Sarepta is also at the frontier of developing next-generation treatments with SRP-5051, a peptide conjugated PMO (phosphorodiamidate morpholino oligomer) that specifically binds exon 51 of dystrophin pre-mRNA. This therapeutic development underscores the company's ongoing commitment to innovation in drug development and personalized medicine for Duchenne muscular dystrophy.

• SRP-9003

This gene therapy program is aimed at addressing limb-girdle muscular dystrophies (LGMD), another group of rare genetic disorders. Through SRP-9003, Sarepta Therapeutics is expanding its reach beyond Duchenne, demonstrating its broad commitment to tackling a wide range of rare genetic conditions.